EKF Diagnostics (LSE:EKF) reported revenue of £25.0 million for the six months ended 30 June 2026, broadly unchanged from the prior-year period, while adjusted EBITDA increased 2.4% to £5.9 million.
The diagnostics group reported a gross margin of 53.0%, with the improvement attributed to product mix and increased sales of β-HB products.
Cash generated from operations remained positive during the period, while the group’s cash balance increased to £16.0 million. EKF also continued its share buyback programme, which reduced the number of shares in issue and contributed to higher earnings per share.
Life Sciences Revenue Supported by β-HB Sales
EKF said its Life Sciences division performed ahead of its expectations, supported by growth in β-HB sales and contract manufacturing.
In the Point-of-Care division, revenue was affected by the timing of customer orders and temporary production constraints. The company said those production issues have since been resolved.
EKF reported a committed order book for the second half of the year and reaffirmed its full-year guidance for revenue and EBITDA growth in line with market consensus.
During the period, the company also added digital capabilities through its acquisition of BEEP Insights and exited its Elkhart site earlier than planned.
EKF Diagnostics Operations
EKF Diagnostics is an AIM-listed diagnostics company headquartered in Penarth, near Cardiff. Its Point-of-Care operations include analysers used in haematology and diabetes, while its Life Sciences business provides specialist enzyme manufacturing and custom products for diagnostic, food and industrial applications.
The company operates four manufacturing sites across the US and Germany and sells its products in more than 120 countries.
Leave a Reply